<PAGE>
 
                                                                    Exhibit 99.1
                                                                    ------------


                              CAUTIONARY STATEMENT

     Integ Incorporated ("Integ" or the "Company"), or persons acting on behalf
of the Company, or outside reviewers retained by the Company making statements
on behalf of the Company, or underwriters, from time to time, may make, in
writing or orally, "forward-looking statements" as defined under the Private
Securities Litigation Reform Act of 1995 (the "Act").  This Cautionary Statement
is for the purpose of qualifying for the "safe harbor" provisions of the Act and
is intended to be a readily available written document that contains factors
which could cause results to differ materially from those projected in such
forward-looking statements.  These factors are in addition to any other
cautionary statements, written or oral, which may be made or referred to in
connection with any such forward-looking statement.

     The following matters, among others, may have a material adverse effect on
the business, financial condition, liquidity, results of operations or
prospects, financial or otherwise, of the Company.  Reference to this Cautionary
Statement in the context of a forward-looking statement shall be deemed to be a
statement that any one or more of the following factors may cause actual results
to differ materially from those which might be projected, forecast, estimated or
budgeted by the Company in such forward-looking statement or statements:

DEVELOPMENT OF NEW TECHNOLOGY; DEPENDENCE ON THE LIFEGUIDE SYSTEM; UNCERTAINTY
OF MARKET ACCEPTANCE

     The Company's future success is entirely dependent upon the successful
development, commercialization and market acceptance of the Lifeguide System,
the development of which is ongoing and the complete efficacy of which has not
yet been demonstrated.  To date, the Company has only tested benchtop
prototypes of its proposed device, and the Company does not expect to produce
commercial prototypes of the Lifeguide Monitor and the Lifeguide Key until the
first quarter of 1997.  There can be no assurance that unforeseen problems will
not occur in research and development, clinical testing, regulatory submissions
and approval, product manufacturing and commercial scale up, marketing or
product distribution.  Any such occurrence could materially delay the
commercialization of the Lifeguide System or prevent its market introduction
entirely.  Further, even if successfully developed, the commercial success of
the Lifeguide System will depend upon its acceptance as a painless, bloodless,
accurate, reliable and cost-effective alternative to existing blood glucose
monitoring techniques.  The glucose monitoring industry is currently dominated
by several companies with established markets and distribution channels.
Because the proposed Lifeguide System will represent a new practice in the
monitoring of glucose levels, the Company is unable to predict how quickly, if
at all, its products will be accepted by members of the medical community and
people with diabetes.  There is no assurance that the Company will ever derive
substantial revenues from the sale of the Lifeguide System.

HISTORY OF OPERATING LOSSES; ACCUMULATED DEFICIT; EXPECTATION OF FUTURE LOSSES

     The Company has generated no revenue and has sustained significant
operating losses each year since its inception.  As of September 30, 1996, the
Company had an accumulated deficit of approximately $15,908,000.  Net losses for
the years ended December 31, 1993, 1994 and 1995 were approximately $683,000,
$2,492,000 and $5,049,000, respectively, and the Company expects such losses to
continue through 1999 and to increase at least through the end of 1998.  The
Company may never generate substantial operating revenues or achieve
profitability.  The Company's ability to generate revenues from operations and
achieve profitability is dependent upon successful development, regulatory
approval and commercialization of the Lifeguide System and the Company's
successful transition from a development stage company to a fully operating
company.

                                      14
<PAGE>
 
LIMITED CLINICAL TESTING EXPERIENCE; UNCERTAINTY OF OBTAINING FDA CLEARANCES

     To date, testing of the Lifeguide System has been performed on benchtop
prototypes solely by Company personnel under controlled circumstances.  The
Company expects to make commercial prototypes of the Lifeguide System available
to people with diabetes for self-testing in the first quarter of 1997 and to use
the data derived from this testing to support a 510(k) notification with the
Food and Drug Administration ("FDA") to permit commercialization of the
Lifeguide System in the United States.  There can be no assurance that the
Company will not encounter problems in clinical testing which will cause the
Company to delay commercialization of the Lifeguide System, and there can be no
assurance that the Lifeguide System will prove to be accurate and reliable on a
consistent basis.  Even if accurate and reliable, there can be no assurance that
such testing will show the Company's product to be safe or effective.  There can
also be no assurance that the required FDA clearances will be obtained on a
timely basis or at all.  Although the Company believes that its products will be
eligible for a 510(k) clearance from the FDA, there can be no assurance that a
full Premarket Approval application (a "PMA") will not be required.  Approval of
a PMA by the FDA would require substantial clinical trials and other
supplemental information regarding the proposed Lifeguide System.  If required,
the preparation and filing of a PMA would materially delay the introduction of
the Lifeguide System.  Further, there can be no assurance that any PMA filed by
the Company would be approved on a timely basis or at all.  In addition, there
can be no assurance that the required FDA clearances or approvals will be
obtained on a timely basis or at all.  The Company has no experience in
obtaining regulatory approval.

HIGHLY COMPETITIVE MARKETS; RISK OF TECHNOLOGICAL OBSOLESCENCE

     The glucose monitoring industry is characterized by continuously evolving
technology and intense competition, and the market is currently dominated by
several companies with established products and distribution channels.  In
addition, other companies are attempting to develop minimally- or non-invasive
glucose monitoring products competitive with the proposed Lifeguide System.
There can be no assurance that the Company's competitors and potential
competitors will not succeed in developing or marketing technologies and
products that will be more accepted in the marketplace than the proposed
Lifeguide System or that would render the Company's technology and proposed
device obsolete or noncompetitive. In addition, numerous researchers are
investigating alternative treatments or cures for diabetes.  If any of these
efforts are successful in reducing the complications associated with diabetes,
the need for the Company's products could be mitigated or become entirely
nonexistent.  Most of the Company's competitors and potential competitors have
substantially greater capital resources, research and development staffs and
facilities than the Company.  In addition, most of the Company's competitors and
potential competitors have substantially greater experience than the Company in
research and new product development, obtaining regulatory approvals and
manufacturing and marketing medical devices.  Competition within the glucose
monitoring industry could also result in reductions of the prices of the
Company's products and the use of purchase incentive programs that could
adversely affect the Company's revenues and profitability.

LACK OF MANUFACTURING CAPABILITY; DEPENDENCE ON CONTRACT MANUFACTURERS AND
SUPPLIERS

     The Company's Lifeguide System is still in development and the Company has
not yet created or manufactured a commercial prototype of its device.  To be
successful, the Company must manufacture the Lifeguide System in compliance with
regulatory requirements, in a timely manner and in sufficient quantities while
maintaining product quality and acceptable manufacturing costs. The Lifeguide
Monitor will be manufactured for the Company by an outside vendor from primarily
off-the-shelf components.  The Lifeguide Key will be assembled by the Company
from components to be purchased from outside suppliers.  However, the Company
presently has no manufacturing contracts or supply agreements and has no
manufacturing capability. In addition, one component of the Lifeguide Monitor is
available from a single source, as is one component of the Lifeguide Key.  In
the event that the 

                                      15
<PAGE>
 
Company is unable to obtain either of these components from their respective
suppliers, the Company would be required to make modifications to its existing
Lifeguide System and to obtain alternative components from alternative
suppliers. Any interruption in the supply of either of these components would
have a material adverse effect on the Company's business, financial condition
and results of operation. Manufacturers often encounter difficulties in scaling
up production of new products, including problems involving production yields,
quality control and assurance, component supplies and shortages of personnel.
There can be no assurance that the Company will be able to achieve and maintain
product quality and reliability when producing the Lifeguide System in the
quantities required for commercialization, nor that the Company will be able to
assemble and manufacture its products at an acceptable cost.

DEPENDENCE ON PATENTS AND PROPRIETARY TECHNOLOGY

     The Company's success will depend in part on its ability to obtain patent
protection for its proposed products and processes, to preserve its trade
secrets and to operate without infringing the proprietary rights of third
parties.  As of the date of this Form 10-Q, no patents have been issued to the
Company with respect to the Lifeguide System.  The Company has applied for six
United States patents and for four corresponding PCT foreign patent covering
certain aspects of the technology underlying the  Lifeguide System, and the
Company has received notice of allowance on two of these patents.  There can be
no assurance, however, that any patents will be issued, that the scope of any
patent protection granted to the Company will prevent competitors from
introducing products competitive with the Lifeguide System or that any of the
Company's patents will be held valid or enforceable if subsequently challenged.
Patenting medical devices involves complex legal and factual questions, and
there is no consistent policy regarding the breadth of claims which issue
pertaining to such technologies.  The Company also relies upon unpatented trade
secrets, and no assurance can be given that others will not independently
develop or otherwise acquire unpatented technologies substantially equivalent to
those of the Company.  In addition, even if the patents for which the Company
has applied are ultimately issued, other parties may hold or receive patents
that contain claims covering the Lifeguide System and which may delay or prevent
the sale of the Lifeguide System or require licenses resulting in the payment of
fees or royalties by the Company in order for the Company to carry on its
business.  There can be no assurance that needed or potentially useful licenses
will be available in the future on acceptable terms or at all.

     There has been substantial litigation regarding patent and other
intellectual property rights in the medical device industry.  Litigation could
result in substantial costs to and a diversion of effort by the Company, but may
be necessary to enforce any patents issued to the Company, protect trade secrets
or know-how owned by the Company, defend the Company against claimed
infringement of the rights of others or determine the scope and validity of the
proprietary rights of others. The Company is not currently a party to any patent
or other litigation. The Company routinely monitors patent issuances by others
in its industry, and as a result recently became aware of a patent that may
relate to a feature of the Lifeguide System.  The Company engaged outside patent
counsel to review the patent, and such counsel rendered its opinion to the
Company that the patent is not infringed by the Company's technology.  In
addition, such counsel advised the Company that if the patent was challenged,
those claims which the Company believes may apply to the Lifeguide System would
be likely to be held invalid based on the existence of prior art not cited by
the patent examiner.  There can be no assurance, however, that the holder of the
patent will not pursue litigation which could be costly to the Company.  An
adverse determination in any litigation, including any litigation commenced by
the holder of the patent referred to above, could subject the Company to
significant liabilities to third parties, require the Company to seek licenses
from or pay royalties to third parties or prevent the Company from
manufacturing, selling or using its proposed products, any of which could have a
material adverse effect on the Company's business and prospects.

                                      16
<PAGE>
 
GOVERNMENT REGULATION; NEED FOR ADDITIONAL GOVERNMENT CLEARANCES

     Government regulation in the United States and other countries is a
significant factor in the Company's business.  The Company's products will be
regulated by the FDA under a number of statutes including the Federal Food, Drug
and Cosmetic Act, as amended (the "FDC Act"), and the Safe Medical Devices Act
of 1990 (the "SMDA").  Manufacturers of medical devices must comply with
applicable provisions of the FDC Act and the SMDA and certain associated
regulations governing the development, testing, manufacturing, labeling,
marketing and distribution of medical devices and the reporting of certain
information regarding their safety.  Both the FDC Act and the SMDA require
certain clearances from the FDA before medical devices, such as the Company's
proposed Lifeguide System, can be marketed.

     The Company has not obtained FDA clearance to market the Lifeguide System.
The regulatory process may delay the marketing of new products for lengthy
periods, impose substantial additional costs and provide an advantage to those
of the Company's competitors who have greater financial resources.  FDA
marketing clearance regulations depend heavily on administrative interpretation.
There can be no assurance that interpretations made by the FDA or other
regulatory bodies, with possible retroactive effect, will not adversely affect
the Company.  There can be no assurance that any such clearance will be obtained
in a timely manner, or at all.  In addition, even if obtained, FDA clearances
are subject to continual review, and if the FDA believes that the Company is not
in compliance with the FDC Act, the SMDA or their associated regulations, it can
institute proceedings to detain or seize the Company's products, require a
recall, enjoin future violations and assess civil and criminal penalties against
the Company, its directors, officers or employees.  The FDA may also withdraw
market approval for the Company's products or require the Company to repair,
replace or refund the cost of any device manufactured or distributed by the
Company.

     The FDC Act will regulate the Company's development, quality control and
manufacturing procedures by requiring the Company to demonstrate compliance with
current Good Manufacturing Practices.  The FDA monitors compliance with these
requirements by requiring manufacturers to register with the FDA, which subjects
them to periodic FDA inspections of their manufacturing facilities.  In order to
ensure compliance with these requirements, the Company will be required to
expend time, resources and effort in the areas of production and quality
control. If violations of the applicable regulations are noted during FDA
inspections, the continued marketing of any products manufactured by the Company
may be halted or adversely affected.

     The Company also plans to eventually distribute its products in several
foreign countries.  The Company's products will be subject to a wide variety of
laws and regulations in these markets.   Generally, the extent and complexity of
the regulation of medical devices is increasing worldwide, with regulations in
some countries already nearly as exhaustive as those applicable in the United
States.  This trend may continue and the cost and time required to obtain
marketing approval in any given country may increase.  There can be no assurance
that any foreign approvals will be allowed on a timely basis or at all.

LACK OF COMMERCIAL SALES OR MARKETING EXPERIENCE

     The Company has no experience in marketing the Lifeguide System and has not
yet entered into any marketing or distribution arrangements for its proposed
Lifeguide System.  There can be no assurance that the Company will be able to
build a suitable sales force or enter into satisfactory marketing arrangements
with third parties when commercial potential develops, if ever, or that its
sales and marketing efforts will be successful.

                                      17
<PAGE>
 
DEPENDENCE ON KEY PERSONNEL; NEED FOR ADDITIONAL PERSONNEL

     The success of the Company is dependent in large part upon the ability of
the Company to attract and retain key management and operating personnel.
Qualified individuals are in high demand and are often subject to competing
offers.  In the future, the Company will need to add additional skilled
personnel in the areas of research and development, sales, marketing and
manufacturing.  There can be no assurance that the Company will be able to
attract and retain the qualified personnel needed for its business.  The loss of
the services of one or more members of the Company's research, manufacturing  or
management group or the inability to hire additional personnel as needed would
likely have a material adverse effect on the Company's business and prospects.

FUTURE CAPITAL REQUIREMENTS; NO ASSURANCE FUTURE CAPITAL WILL BE AVAILABLE

     The Company expects that the proceeds from its initial public offering
consummated in July 1996, along with its existing cash, will be sufficient to
fund the Company's operations until late 1998.  The Company may require
substantial additional funds to meet its working capital requirements for a
full-scale commercial introduction of its proposed Lifeguide System.  In order
to meet its needs beyond this period, the Company may be required to raise
additional funds through public or private financings, including equity
financings.  Adequate funds for the Company's operations, whether from financial
markets or from other sources, may not be available when needed on terms
attractive to the Company or at all.  Insufficient funds may require the Company
to delay, scale back or eliminate some or all of its programs designed to
facilitate the commercial introduction of the Lifeguide System or prevent such
commercial introduction altogether.

UNCERTAINTY OF THIRD PARTY REIMBURSEMENT

     Sales of the Company's proposed products in certain markets will be
dependent in part on availability of adequate reimbursement for personal glucose
monitoring products from third-party healthcare payors, such as government and
private insurance plans, health maintenance organizations and preferred provider
organizations.  Third party payors are increasingly challenging the pricing of
medical products and services.  There can be no assurance that adequate levels
of reimbursement will be available to enable the Company to achieve market
acceptance of the Lifeguide System or maintain price levels sufficient to
realize an appropriate return on its investment in the development or
manufacture of its proposed Lifeguide System.  Without adequate support from
third-party payors, the market for the Company's Lifeguide System may be
limited.

PRODUCT LIABILITY RISK; LIMITED INSURANCE COVERAGE

     The Company faces an inherent business risk of exposure to product
liability claims in the event that an end-user is adversely affected by its
prospective products.  The Company currently carries a product liability
insurance policy covering the Company's clinical testing with an aggregate limit
of $1.0 million.  Although the Company expects to obtain product liability
insurance coverage in connection with the commercialization of the Lifeguide
System, there can be no assurance that such insurance will be available on
commercially reasonable terms, or at all, or that such insurance, even if
obtained, would adequately cover any product liability claim.  A product
liability or other claim with respect to uninsured liabilities or in excess of
insured liabilities could have a material adverse effect on the business and
prospects of the Company.

     The foregoing review of factors pursuant to the Act should not be construed
as exhaustive or as any admission regarding the adequacy of disclosures made by
the Company prior to the effective date of the Act.

                                      18